ArriVent BioPharma Inc. C...
(AVBP)
undefined
undefined%
At close: undefined
26.72
0.49%
After-hours Dec 13, 2024, 04:00 PM EST
Income Statement (Annual)
Get detailed income statement breakdowns, uncovering revenue,
expenses, and much more.
Year | FY23 | FY22 | FY21 |
Revenue | - | - | - |
Cost of Revenue | - | - | - |
Gross Profit | - | - | - |
Operating Income | -74.59M | -36.91M | -8.70M |
Interest Income | 5.26M | - | - |
Pretax Income | -69.33M | -36.91M | -51.61M |
Net Income | -69.33M | -36.91M | -51.61M |
Selling & General & Admin | 9.71M | 6.47M | 2.26M |
Research & Development | 64.88M | 30.43M | 6.43M |
Other Expenses | - | - | - |
Operating Expenses | 74.59M | 36.91M | 8.70M |
Interest Expense | - | - | - |
Selling & Marketing Expenses | - | - | -754.00K |
Cost & Expenses | 74.59M | 36.91M | 8.70M |
Income Tax | - | -36.91M | -11.59M |
Shares Outstanding (Basic) | 31.96M | 33.49M | 33.49M |
Shares Outstanding (Diluted) | 31.96M | 33.49M | 33.49M |
EPS (Basic) | -2.17 | -1.1 | -1.54 |
EPS (Diluted) | -2.17 | -1.1 | -1.54 |
EBITDA | -74.59M | -36.91M | -51.61M |
Depreciation & Amortization | - | 36.91M | 11.59M |